A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience

JOURNAL ARTICLE published May 2020 in Breast Cancer Research and Treatment

Authors: J. Watanabe | M. Saito | Y. Horimoto | S. Nakamoto